Qrons (QRON) 10-K 15 Apr 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Apr. 10, 2024	Jun. 30, 2023
Cover [Abstract]
Entity Registrant Name	QRONS INC.
Entity Central Index Key	0001689084
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		13,649,789
Entity Public Float			$ 1,327,916
Document Annual Report	true
Document Transition Report	false
Document Fin Stmt Error Correction Flag	false
Entity File Number	000-55800
Entity Incorporation State Country Code	WY
Entity Tax Identification Number	81-3623646
Entity Address Address Line 1	28-10 Jackson Avenue #26N
Entity Address City Or Town	Long Island City
Entity Address State Or Province	NY
Entity Address Postal Zip Code	11101
City Area Code	212
Local Phone Number	945-2080
Security 12g Title	Common Stock, $0.0001 par value
Entity Interactive Data Current	Yes
Auditor Name	Green Growth CPAS
Auditor Location	Los Angeles, California
Auditor Firm Id	6580

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 420	$ 3,069
Total current assets	420	3,069
TOTAL ASSETS	420	3,069
Current liabilities
Accounts payable and accrued liabilities	155,357	128,285
Accounts payable and accrued liabilities - related party	83,291	42,671
Demand loans, related party	85,873	85,873
Advances from related party	424,500	358,500
Unsecured short-term advances	100,000	100,000
Convertible notes, net of debt discount	185,974	208,247
Derivative liabilities	288,720	358,775
Total current liabilities	1,323,715	1,282,351
Convertible notes, net of debt discount	80,000	0
Derivative liabilities	84,998	0
Total long term liabilities	164,998	0
Total liabilities	1,488,713	1,282,351
Stockholders' deficit
Series A Preferred stock: $0.001 par value; 10,000 shares authorized; 2,000 shares issued and outstanding	2	2
Common stock, $0.0001 par value: 100,000,000 shares authorized; 13,649,789 and 13,439,789 shares issued and outstanding as of December 31, 2023 and 2022, respectively	1,365	1,344
Additional paid-in capital	8,834,631	8,254,316
Accumulated deficit	(10,324,291)	(9,534,944)
Total stockholders' deficit	(1,488,293)	(1,279,282)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 420	$ 3,069

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
BALANCE SHEETS
Series A Preferred Shares, par value	$ 0.001	$ 0.001
Series A Preferred Shares, authorized	10,000	10,000
Series A Preferred Shares, shares issued	2,000	2,000
Series A Preferred Shares, shares outstanding	2,000	2,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,649,789	13,439,789
Common stock, shares outstanding	13,649,789	13,439,789

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
STATEMENTS OF OPERATIONS
Net sales	$ 0	$ 0
Operating expenses:
Research and development expenses	462,459	194,406
Professional fees	70,946	70,199
General and administrative expenses	110,272	365,024
Total operating expenses	643,677	629,629
Loss from operations	(643,677)	(629,629)
Other income (expense)
Loss on extinguishment of debt	(33,932)	0
Interest expense	(105,589)	(135,654)
Change in derivative liabilities	(6,149)	31,766
Total other income (expense)	(145,670)	(103,888)
Net loss	$ (789,347)	$ (733,517)
Net loss per common shares (basic and diluted)	$ (0.06)	$ (0.06)
Weighted average shares outstanding
(basic and diluted)	13,528,310	13,299,652

STATEMENTS OF CHANGES IN STOCKH

STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY DEFICIT - USD ($)	Total	Common Stock	Series A, Preferreds Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2021		13,289,789	2,000
Balance, amount at Dec. 31, 2021	$ (1,102,745)	$ 1,329	$ 2	$ 7,697,351	$ (8,801,427)
Issuance of common stock to noteholder, shares		150,000
Issuance of common stock to noteholder, amount	76,350	$ 15		76,335
Stock options granted to officers	320,420			320,420
Stock options granted to non-employees as research and development costs	160,210			160,210
Net loss for the year	(733,517)				(733,517)
Balance, shares at Dec. 31, 2022		13,439,789	2,000
Balance, amount at Dec. 31, 2022	(1,279,282)	$ 1,344	$ 2	8,254,316	(9,534,944)
Stock options granted to non-employees as research and development costs	465,345			465,345
Net loss for the year	(789,347)				(789,347)
Issuance of common stock for note amendment, shares		150,000
Issuance of common stock for note amendment, amount	52,500	$ 15		52,485
Stock award, shares		60,000
Stock award, amount	16,680	$ 6		16,674
Stock options granted to non-employees as consulting fees	45,811			45,811
Balance, shares at Dec. 31, 2023		13,649,789	2,000
Balance, amount at Dec. 31, 2023	$ (1,488,293)	$ 1,365	$ 2	$ 8,834,631	$ (10,324,291)

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash Flows From Operating Activities
Net loss	$ (789,347)	$ (733,517)
Adjustments to reconcile net loss to net cash used by operating activities:
Stock options issued for research and development expense	465,345	160,210
Stock options issued for consulting services	45,811	0
Stock options granted for officer compensation	0	320,420
Stock award	16,680	0
Loss on debt extinguishment	33,932	0
Non cash interest expense	38,000	62,100
Accretion of debt discount	35,091	56,196
Change in derivative liabilities	6,149	(31,766)
Changes in operating assets and liabilities:
Increase accounts payable and accrued liabilities	39,070	46,509
Increase accounts payable and accrued liabilities - related party	40,620	15,352
Net cash used by operating activities	(68,649)	(104,496)
Cash Flows From Investing Activities
Net cash provided from (used by) investing activities	0	0
Cash Flows From Financing Activities
Proceeds from related party advances	66,000	72,500
Net cash provided from financing activities	66,000	72,500
Decrease in cash and cash equivalents	(2,649)	(31,996)
Cash at beginning of year	3,069	35,065
Cash at end of period	420	3,069
SUPPLEMENTAL DISCLOSURES
Interest paid	0	0
Income taxes paid	0	0
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Common stock issued under amended note	52,500	76,350
Debt discount from amended convertible note	29,461	24,634
Accrued interest payable modified to Note amended	12,000	9,200
Convertible notes - related party modified to 6% promissory note	0	25,000
Accrued interest payable - related party modified to 6% promissory note	0	10,873
Derivative liability associated with warrants	$ 2,012	$ 15,416

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2023
Description of Business and Basis of Presentation
Description of Business and Basis of Presentation	Note 1 – Description of Business and Basis of Presentation Organization and Nature of Business: Qrons Inc. (“Qrons” or the “Company”) was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. and changed its name to Qrons Inc., effective August 8, 2017. The Company’s common stock was approved by the Financial Industry Regulatory Authority (“FINRA”) for quotation on the OTC pink sheets under the symbol “BLMB” as of July 3, 2017. FINRA announced the Company’s name change to Qrons Inc. on August 9, 2017. The new name and symbol change to “QRON” for the OTC Market was effective August 10, 2017. The Company’s common stock commenced trading on the OTCQB Venture Market on August 12, 2019. The Company is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, which is becoming the most prominent and rapidly growing worldwide cause of illness and death. Our approach is to seek to engage in strategic arrangements with companies, universities and, scientists that are developing unique know how and intellectual properties in the fields of, stem cells, antibiotic resistant drug development and tissue engineering, for deployment in the fight against neuronal and infectious diseases. Our search is focused on researchers based in Israel, a country which is world-renowned for biotech innovations and where our researchers are based. The Company’s principal executive office is located at 28-10 Jackson Avenue, Long Island City, #26N, New York 11101.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Financial Statements: Fiscal year end: Use of Estimates: Cash Equivalents: Research and Development Costs: Research and Development Advertising and Marketing Costs: Related Parties: Stock Based Compensation and Other Share-Based Payments: Compensation - Stock Compensation Fair Value of Financial Instruments ASC 820, Fair Value Measurements Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities as of December 31, 2023 and 2022: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of December 31, 2023: Liabilities Derivative liabilities $ - $ - $ 373,718 As of December 31, 2022: Liabilities Derivative liabilities $ - $ - $ 358,775 Warrants: Derivatives and Hedging Income taxes: Income Taxes Basic and Diluted Loss Per Share Earnings Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The table below reflects the potentially dilutive securities outstanding during each reporting period: December 31, 2023 December 31, 2022 Research warrants at 3% of issued and outstanding shares 409,494 403,194 Convertible notes 846,009 460,000 Series A preferred shares 700 700 Stock options vested 3,883,336 4,328,332 Stock options not yet vested 899,997 - Stock purchase warrants 295,000 295,000 Total 6,334,536 5,487,226 Recently Issued Accounting Pronouncements Adopted In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company’s operations, financial position or cash flows.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2023
Going Concern
Going Concern	Note 3 – Going Concern The Company has experienced net losses to date and has not generated revenues from operations. The Company raised proceeds totaling $72,500 in unsecured advances from related parties in the year ended December 31, 2022 and a further $66,000 in unsecured advances from related parties during the current year ended December 31, 2023. Currently, the Company does not have significant cash or other material assets, nor does it have operations or a source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The Company’s officers or principal shareholders are committed to making advances or loans to pay for ongoing operational costs. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which also raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing, and continued support from its officers and directors. There can be no assurance that financing, whether debt or equity, will be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. In addition, if the Company is unable to obtain adequate financing from the capital markets, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.

Convertible Note Related Party

Convertible Note Related Party and Derivative Liabilities	12 Months Ended
	Dec. 31, 2023
Convertible Note Related Party and Derivative Liabilities
Convertible Note Related Party and Derivative Liabilities	Note 4 – Convertible Note – Related Party and Derivative Liabilities On September 1, 2016, the Company entered into a convertible debenture agreement with Decagon LLC, doing business as CubeSquare, LLC (“CubeSquare”), of which the Company’s Chief Executive Officer is the managing partner and its President is a 25% owner of CubeSquare. The Company received proceeds of $10,000 during fiscal 2016 (“Note 1”). Note 1 bears interest at 8% per annum and was due on September 1, 2017. Interest accrues from September 1, 2016 and is payable on maturity. Interest is payable, at the lender’s option, in cash or common stock. Any portion of the loan and unpaid interest is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price of the greater of (i) $0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender. On September 29, 2017, the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018; on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019; on November 6, 2019, the Company further amended Note 1 to extend the maturity date to September 1, 2020; on October 30, 2020, the Company further amended Note 1 to extend the maturity date to September 1, 2021; and on October 7, 2021, the Company further amended Note 1 to extend the maturity date to September 1, 2022 under the same terms and conditions. On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and was due on September 27, 2018. Interest accrues from September 27, 2017 and is payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. On September 9, 2018, Note 2 was amended to extend the maturity date to September 27, 2019. On November 6, 2019, Note 2 was amended to extend the maturity date to September 27, 2020; on October 30, 2020 Note 2 was amended to extend the maturity date to September 27, 2021; and further on October 7, 2021 Note 2 was amended to extend the maturity date to September 27, 2022. On September 27, 2022 the Board and the noteholder agreed to cancel the two convertible notes and in full satisfaction of such outstanding debt to issue a new 6% non-convertible promissory note to CubeSquare in the principal amount of $35,873 (the “New Note”), representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022. The Company analyzed the amendment to Note 1 and Note 2 under ASC 815-10-15-83 and concluded that the conversion feature within these two convertible Notes meet the definition of a derivative. The Company estimated the fair value of the derivative at each report date using the Black-Scholes valuation model to value the derivative liability related to the variable conversion rate. There is no derivative liability associated with the New Note given the absence of a conversion feature. The carrying value of these convertible notes is as follows: December 31 2023 December 31, 2022 Face value of certain convertible notes $ - $ 25,000 Convertible notes extinguished - (25,000 ) Carrying value $ - $ - Interest expenses associated with the convertible notes are as follows: For Years Ended December 31, 2023 2022 Interest on the convertible notes $ - $ 1,424 As of December 31, 2023 and December 31, 2022, the unpaid interest balance under accounts payable and accrued liabilities – related party was $0. As a result of the application of ASC 815, the fair value of the derivative liability associated with the conversion feature is summarized as follows: Balance at December 31, 2020 $ 61,682 Change in fair value 11,417 Balance at December 31, 2021 73,099 Change in fair value (73,099 ) Balance at December 31, 2022 $ - The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of September 27, 2022 and December 31, 2021 and the commitment date: Commitment Date December 31, 2021 September 27, 2022 Expected dividends 0 0 0 Expected volatility 101%-103 % 181%-182 % 101%~56 % Expected term 0.92 - 1 year 0.67 - 0.74 year 0 year Risk free interest rate 1.33 % 1.06 % 2.22 %

Convertible Note and Derivative

Convertible Note and Derivative Liabilities	12 Months Ended
	Dec. 31, 2023
Convertible Note and Derivative Liabilities
Convertible Note and Derivative Liabilities	Note 5 – Convertible Note and Derivative Liabilities (1) 8% Convertible notes with warrants issued in December 2019 and February 2020 In December 2019, we issued and sold in a private offering 8% convertible notes in the aggregate principal amount of $70,000. Such notes were due on December 31, 2021 and are convertible into shares of our common stock at a conversion price for each share of common stock equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) so long as lower than (a) or (b), such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00. The Company extended the maturity date of the notes to December 2022 upon initial maturity, and further extended the maturity date to December 2023 and subsequently, December 2025 under the same terms and conditions. The balance owing on the note is reflected on the Company’s balance sheets as a long term liability. On February 19, 2020 we issued and sold in a private offering an 8% convertible note in the principal amount of $10,000. The note is due on February 19, 2022 and is convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; or (c) such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 10,000 shares of common stock at an exercise price of $1.00. The Company extended the maturity date to February 2023 upon initial maturity, and further extended the maturity date to February 2024 and subsequently, February 2026 under the same terms and conditions. The balance owing on the note is reflected on the Company’s balance sheets as a long-term liability. The carrying value of these convertible notes is as follows: December 31, 2023 December 31, 2022 Face value of certain convertible notes, long term $ 80,000 $ 80,000 Carrying value, long term $ 80,000 $ 80,000 Interest expenses associated with the convertible notes are as follows: Years Ended December 31, 2023 2022 Amortization on debt discount $ - $ 541 Interest on the convertible notes 6,400 6,400 Total $ 6,400 $ 6,941 As of December 31, 2023 and December 31, 2022, the unpaid interest balance under accounts payable and accrued liabilities was $25,669 and $19,269, respectively. The convertible notes qualify for derivative accounting and bifurcation under ASC 815. As of December 31, 2023 and December 31, 2022, the fair value of the derivative liability associated with the conversion feature is summarized as follows: Balance at December 31, 2021 $ 157,490 Change in fair value (100,457 ) Balance at December 31, 2022 57,033 Change in fair value 27,965 Balance at December 31, 2023 $ 84,998 At December 31, 2023, as a result of the extension to the maturity dates the derivative liability is reflected in long-term liabilities. The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of December 31, 2023 and December 31, 2022 and the commitment date: Commitment Date December 31, 2022 December 31, 2023 Expected dividends 0 0 0 Expected volatility 154%-173 % 194.20%-201.98 % 170.40%-224.62 % Expected term 2.10 years 1.08 - 1.22 years 2.08 – 2.22 years Risk free interest rate 1.42-1.65 % 4.41 % 4.23 % (2) 8% Convertible note with warrants issued on June 15, 2021 On June 15, 2021, the Company entered into a note purchase agreement with Quick Capital, LLC (“Quick Capital”) pursuant to which the Company issued a twelve-month convertible promissory note in the principal amount of $115,000 for a $100,000 investment (the “Quick Note”), which included an original issuance discount of 10% and a $3,500 credit for legal and transaction costs. In connection with the Quick Note issuance, Quick Capital was also issued a five-year warrant (the “Quick Warrant”) to purchase up to an aggregate of 115,000 shares of the Company’s common stock at an exercise price of $1.00 per share (the “Quick Warrant Shares”) subject to adjustments for dilutive issuances at lower prices. The Quick Note is convertible into shares of common stock at a conversion price of $0.50 per share. If delivery of the conversion shares is not timely made, the Company is obligated to pay Quick Capital $2,000 for each day that the delivery is late as liquidated damages. The conversion price of the Quick Note will be reduced if the Company issues common stock or grants derivative securities for consideration at a price less than the conversion price to the amount of the consideration of such dilutive issuance. The Quick Note may not be prepaid. The Company is subject to significant cash penalties if the Company defaults on the Quick Note or in the event shares are not issued in a timely manner when a notice of conversion is provided. If an event of default occurs, the Quick Note will become immediately due and payable in an amount equal to 150% of the then outstanding principal amount of the Quick Note plus any interest or amounts owing to Quick Capital. The default provisions are based on the type of default and include a penalty of 50% of the principal plus accrued interest due (the “Default Sum”) and a parity value of the Default Sum based on the effective conversion of the Quick Note on the date of payment of the default and the maximum stock value during the period between the default date and the payment date. As of June 15, 2022, the Note and accrued interest totaling $124,200 was not repaid on maturity, constituting an event of default increasing the repayment value of the note to an amount equal to 150% of the principal balance and accrued interest outstanding, or $186,300. On December 7, 2022, the Company and Quick Capital amended the Note to extend the maturity date thereof to June 15, 2023, and amended the Warrant maturity date to June 15, 2027. Further Quick Capital agreed to reduce the outstanding balance of the Note from $186,300 to $150,000 in consideration for the issuance of 150,000 shares of unregistered, restricted common stock valued at $76,350. As of June 15, 2023, the Note and accrued interest totaling $162,000 was not repaid on maturity, constituting an event of default increasing the repayment value of the note to an amount equal to 150% of the principal balance and accrued interest outstanding, or $243,000. On June 15, 2023, the Company and Quick Capital amended the Note to extend the maturity date thereof to June 15, 2024, and amended the Warrant maturity date to June 15, 2028. Further Quick Capital agreed to reduce the outstanding balance of the Note from $243,000 to $200,000 in consideration for the issuance of 150,000 shares of unregistered, restricted common stock valued at $52,500. The unpaid balance of the Note continues to accrue interest at 8% per annum. The Company valued the embedded default derivative liability of the Quick Note and the Quick Warrant liability, including the full ratchet reset feature, using Monte Carlo models. The fair value of the Quick Note and Quick Warrant embedded default derivatives liability has been valued as of December 31, 2023 and December 31, 2022. The carrying value of the Quick Note is as follows: December 31, 2023 December 31, 2022 Face value of Quick Note $ 200,000 $ 150,000 Less: unamortized discount (14,024 ) (21,753 ) Carrying value $ 185,976 $ 128,247 Interest expenses associated with the conversion feature are as follows: Years ended December 31, 2023 2022 Amortization of debt discount $ 35,091 $ 55,655 Default interest 38,000 62,100 Interest on the convertible notes 19,934 4,973 Total $ 93,025 $ 122,728 As of December 31, 2023 and December 31, 2022, the unpaid interest balance under accounts payable and accrued liabilities was $8,723 and $789, respectively. The loss related to extinguishment on June 15, 2023 is as follows: 150,000 common stock issued $ 52,500 Extinguish derivative liability – convertible note (22,679 ) Unamortized debt discount 2,099 Derivative Liability associated with warrants 2,012 Loss on extinguishment of debt upon amended $ 33,932 As a result of the application of ASC 815 as of December 31, 2023 and December 31, 2022, the fair value of the derivative liability associated with the conversion feature is summarized as follows: Balance at December 31, 2022 $ 301,742 Extinguish – convertible note associated with amended (22,679 ) Debt discount, day one, amended convertible note payable 29,461 Derivative Liability associated with warrants 2,012 Change in fair value – convertible note 10,766 Change in fair value – warrants (32,582 ) Balance at December 31, 2023 $ 288,720 The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of June 15, 2023, December 31, 2023 and December 31, 2022 and the commitment date: Convertible note: Commitment Date December 31, 2022 December 31, 2023 June 15, 2023 Expected dividends 0 0 0 0 Expected volatility 307.10 % 119.70 % 176.9 % 95.60 % Expected term 1 year 0.45 years 0.46 year 1 year Risk free interest rate 0.18 % 4.37 % 4.78 % 4.83 % Warrants: Commitment Date December 31, 2022 December 31, 2023 June 15, 2023 Expected dividends 0 0 0 0 Expected volatility 201.70 % 219.10 % 210.80 % 207.50 % Expected term 5 years 4.45 years 4.46 years 5.00 years Risk free interest rate 0.65 % 4.27 % 4.53 % 4.53 %

Unsecured ShortTerm Advance fro

Unsecured ShortTerm Advance from Third Party	12 Months Ended
	Dec. 31, 2023
Unsecured ShortTerm Advance from Third Party
Unsecured Short-Term Advance from Third Party	Note 6 – Unsecured Short-Term Advance from Third Party On June 20, 2019, the Company received $100,000 from a third party in the form of an unsecured, demand, non-interest-bearing, short-term advance to meet its operating needs. The advance remains outstanding at December 31, 2023 and 2022.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions
Related Party Transactions	Note 7 – Related Party Transactions (1) Demand Loan from related party On May 1, 2019, the Company issued a promissory note (the “Note”) to CubeSquare in the principal amount of $50,000. The Company’s Chief Executive Officer is the managing partner and the Company’s President is a 25% owner of CubeSquare. The Note bears interest at the rate of 8% per annum and is due and payable by the Company upon demand from CubeSquare. The Company recorded interest expenses of $4,011 and $4,000 for the years ended December 31, 2023 and 2022. On September 27, 2022 the Board and the related party noteholder agreed to cancel two convertible notes issued to Cubesquare and in full satisfaction of such outstanding debt to issue a new 6% promissory note (Ref: Note 4) in the principal amount of $35,873, representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022. The Company recorded interest expenses of $2,152 and $560 for the years ended December 31, 2023 and 2022. As of December 31, 2023 and December 31, 2022, the unpaid interest balance under accounts payable and accrued liabilities – related party in respect of the aforementioned notes was $21,397 and $15,234, respectively. (2) Advances from Related Parties During the year ended December 31, 2019, the Company received $135,000 from Jonah Meer, its Chief Executive Officer, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $70,000 from Jonah Meer. An additional $72,500 in advances was received from Mr. Meer during the year ended December 31, 2022. An additional $61,000 in advances was received from Mr. Meer during the year ended December 31, 2023. Mr. Meer is owed $338,500 and $277,500 in respect to these advances at December 31, 2023 and December 31, 2022, respectively. On August 20, 2019, the Company received $50,000 from Ido Merfeld, its President, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $21,000 from Ido Merfeld. During the year ended December 31, 2023, the Company received an additional $5,000 from Ido Merfeld. Mr. Merfeld is owed $76,000 and $71,000 in respect to these advances at December 31, 2023 and December 31, 2022, respectively. During the year ended December 31, 2020, the Company received $10,000 from CubeSquare in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs which amount is outstanding as of December 31, 2023 and December 31, 2022. (3) Others Jonah Meer, the Company’s Chief Executive Officer, made payments of $33,860 to various vendors during the year ended December 31, 2023. The balance payable to Mr. Meer of $60,129 and $26,268 is reflected in accounts payable, related party as of December 31, 2023 and December 31, 2022, respectively. Ido Merfeld, the Company’s President, made payments to various vendors in the aggregate amount of $596 during the year ended December 31, 2023. The balance payable to Mr. Merfeld of $1,765 and $1,169 is reflected in accounts payable, related party as of December 31, 2023 and 2022.

Intellectual Property License A

Intellectual Property License Agreement and Sponsored Research Agreement	12 Months Ended
	Dec. 31, 2023
Intellectual Property License Agreement and Sponsored Research Agreement
Intellectual Property License Agreement and Sponsored Research Agreement	Note 8 – Intellectual Property License Agreement and Sponsored Research Agreement Dartmouth College – Intellectual Property License Agreement On October 2, 2019, the Company entered into an intellectual property license agreement (the “Intellectual Property License Agreement”) pursuant to which Dartmouth granted the Company an exclusive world-wide license under the patent application entitled “Mechanically Interlocked Molecules-based Materials for 3D Printing” in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services. The license grant includes the right of the Company to sublicense to third parties subject to the terms of the Agreement. The Agreement provided for: (i) a $25,000 license issue fee; (ii) an annual license maintenance fee of $25,000, until the first commercial sale of a licensed product or service; (iii) an earned royalty of 2% of net sales of licensed products and services by the Company or a sublicensee; (iv) 15% of consideration received by the Company under a sublicense; and (v) beginning in the first calendar year after the first commercial sale, an annual minimum royalty payment of $500,000, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter. The Company will also reimburse Dartmouth for all patent preparation, filing, maintenance and defense costs. Under the Agreement, the Company was required to diligently proceed with the development, manufacture and sale of licensed products and licensed services, including funding at least $1,000,000 of research in each calendar year beginning in 2019 and ending with the first commercial sale of a licensed product; filing an IND/BLA (or equivalent) with the FDA or a comparable European regulatory agency before the four-year anniversary and make the first commercial sale of a licensed product before the twelve-year anniversary of the effective date of the Agreement and achieve annual net sales of at least $50,000,000 by 2033. If the Company failed to perform any of these obligations, Dartmouth has the option to terminate the Agreement or change the exclusive license to a nonexclusive license. As the Company failed to fulfill its requirements under the Agreement Dartmouth declared the Company in default in August 2023, and terminated the license. The Company and Dartmouth also agreed in February 2024 to add Professor Chenfeng Ke and Qianming Lin, both formerly of Dartmouth as co-inventors of the patent entitled Techniques for Promoting Neuronal Recovery and to add Dartmouth as co-owner of the patent together with Qrons. As of December 31, 2023, the Company is indebted to Dartmouth for $50,000 of unpaid annual license fees and $4,877 of unpaid reimbursable patent maintenance costs. The Company’s sponsored research agreement, pursuant to which the Company funded research conducted by Dartmouth of mutual interest to the parties terminated by its terms in July 2020.

License Agreement Term Sheet an

License Agreement Term Sheet and Advisory Board Member Consulting Agreement	12 Months Ended
	Dec. 31, 2023
License Agreement Term Sheet and Advisory Board Member Consulting Agreement
License Agreement Term Sheet and Advisory Board Member Consulting Agreement	Note 9 –License Agreement Term Sheet and Advisory Board Member Consulting Agreement On July 17, 2023, the Company entered into a License Agreement Term Sheet (the “Agreement”) with Professors Benjamin Sredni and Michael Albeck (the “Professors”) and Dr. Ido Merfeld (“Merfeld), the Company’s President and co-Founder. Under the Agreement the Professors, inventors of certain patents, applications, processes and who possess certain related know-how particularly as to AS101 Tellurium based compounds, (the “Background IP”) agreed to license the Background IP to Qrons. Merfeld is the inventor of certain patents and possesses certain related know-how particularly as to Pseudopolyrotaxanes and Cyclodextrins, all owned by the Company (“Qrons IP”). The Professors granted Qrons an exclusive world-wide, perpetual license to the Background IP, unless the Background IP is returned should Qrons fail to meet certain fundraising and prosecution milestones. The Background IP, independently or together with the Qrons IP will be used as part of a new research program allowing for the use of all Background IP by Qrons to experiment and commercialize the therapeutic effect of certain Tellurium based compounds on antibiotic resistance bacterial infections, Sepsis and Traumatic brain injuries (“Tellurium Research”). The Tellurium Research will be allowed to expand to include other indications as progress warrants and agreed by the parties. The Professors and Merfeld as co-inventors will enter into a new patent filing for treating sepsis with certain Tellurium based compounds independently and in combination with Cyclodextrins, to be known as the “New Patent”. The New Patent will be assigned to Qrons, subject to Qrons rights under the Agreement. As part of the Tellurium Research program the Professors will join Qrons’ Scientific Advisory Board. All new intellectual properties and/or Know-how discovered and/or generated by The Tellurium Research (“Forward IP”) will be the sole property of Qrons. All the Background IP will remain to be the sole property of the Professors until an Exit Event occurs. All additional patents developed, invented or otherwise during the course of the Tellurium Research will be filed, prosecuted, and maintained by Qrons. Qrons and the Professors will share the expenses relating to the filing, prosecution and maintenance of the provisional period of the New Patent. Thereafter, all expenses related to the New Patent shall be the sole responsibility of Qrons. Qrons is tasked with raising $2 million funds to support Tellurium Research. If within a year after the commencement of the Agreement, Qrons fails to raise at least $2 million, the license will be terminated unless agreed otherwise by the parties. If Qrons shall (i) fail to prosecute and maintain in due order the New Patent or (ii) fail to launch a Phase 1 program with the FDA or a comparable European regulatory agency for at least one Tellurium based treatment on or before the three-year (3) anniversary of the date of the Agreement, then the Professors may terminate the license. In the case of termination of the Agreement, Qrons shall at the request of the Professors transfer to the Professors & Merfeld ownership of the New Patent as well as the files, documents, research and new know how, in relation to the sepsis research. As consideration for joining the Scientific Advisory Board, The Professors each received a grant of 150,000 common stock options exercisable at $0.50 with one-third (1/3) being immediately exercisable, and an additional one-third (1/3) exercisable on each of the first- and second-year anniversary dates of the Agreement. Each option shall have a 3-year term for which to exercise the option. Adv. Avichai Isaschar and Hananel Levy will join the Company’s Business Advisory Board and as consideration each received a grant of 50,000 common stock options exercisable at $1.00 each with one-third (1/3) being immediately exercisable, and an additional one-third (1/3) exercisable on each of the first- and second-year anniversary dates of the Agreement. Each option shall have a 3-year term for which to exercise the option. In consideration of the Background IP, Qrons issued to the Professors, to be held as directed by them a total of 800,000 common stock options to purchase shares of Qrons common stock at an exercise price of $1.00 per share, fifty percent (50%) which shall be exercisable on the date of execution of the Agreement and the balance exercisable 1 year from the date of the Agreement. Should the Professors request to receive back the rights to the New Patent “all un-exercised options immediately expire.” In consideration of licensing the Background IP, Qrons shall pay the Professors an earned Royalty of 2% (1% each) Net Sales of any Tellurium based transactions, anywhere in the World and pay to the Professors fifteen percent (15%) of all Sublicense Consideration received by Qrons and each Affiliate under a Sublicense. In the case of a Qrons Exit Event (as defined in the Agreement) the Professors shall transfer full ownership of the Background IP to Qrons and in exchange receive two percent (2%) (1% each) of any consideration received by Qrons as part of such Exit Event. On October 1, 2023, the Company entered into an Advisory Board Member Consulting Agreement (the “Agreement”) with Shiri Navon-Venezia (“Venezia”) whereunder Venezia shall provide advisory and consulting services to the Company as part of the Company’s Scientific Advisory Board. As consideration for the services, Venezia has been granted 100,000 three-year stock options at an exercise price of $0.50 per share of which 33,334 stock options shall vest immediately, 33,333 stock options vest on the one-year anniversary date of the Agreement and the remaining 33,333 stock options vest on the two-year anniversary date of the Agreement, provided Venezia is still providing services to the Company. On October 1, 2023, the Company entered into an Advisory Board Member Consulting Agreement (the “Agreement”) with Dr. Motti Ratmansky (“Ratmansky”) whereunder Ratmansky shall continue to provide advisory and consulting services to the Company as part of the Company’s Scientific Advisory Board. As consideration for the services Ratmansky has been granted a five (5) year fully vested stock option to purchase 50,000 shares of the Company’s common stock at an exercise price of $2.00 per share. On November 1, 2023, the Company entered into an Advisory Board Member Consulting Agreement (the “Agreement”) with Dr. Paul Kaye (“Kaye”) whereunder Kaye shall provide advisory and consulting services to the Company as part of the Company’s Scientific Advisory Board. As consideration for the services Kaye has been granted 50,000 three-year stock options at an exercise price of $2.00 per share of which 16,666 vest immediately, 16,667 stock options vest on the one-year anniversary date of the Agreement and the remaining 16,667 stock options vest on the two-year anniversary date of the Agreement, provided Kaye is still providing services to the Company.

Stock Plan

Stock Plan	12 Months Ended
	Dec. 31, 2023
Stock Plan
Stock Plan	Note 10 – Stock Plan 2016 Stock Option and Stock Award On December 14, 2016, the Board adopted the Company’s 2016 Stock Option and Stock Award Plan (the “Plan”). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Board. The Company has reserved 10 million shares for issuance under the Plan. (a) Stock Options granted to Science Advisors, Business Advisors, Professors and employees On December 22, 2022, the Board granted a five-year option to purchase 325,000 shares of common stock to a scientific advisor. The options have an exercise price of $2.00 per share, are immediately exercisable and were expensed on issue date. During the year ended December 31, 2022, various fully vested three-year stock options to purchase 145,000 shares of common stock of the Company previously granted to science advisors and employees expired unexercised. On July 17, 2023, under the License Agreement Term Sheet (ref: Note 9) the Board awarded Professors the following three-year stock options: (i) an immediately exercisable option to purchase 266,668 shares of common stock at an exercise price of $1.00 per share, (ii) an option to purchase 266,666 shares of common stock exercisable on July 15, 2024 at an exercise price of $1.00 per share and (iii) an option to purchase 266,666 shares of common stock exercisable on July 15, 2025 at an exercise price of $1.00 per share, provided the advisors are still providing services to the Company. On July 17, 2023, under the License Agreement Term Sheet (ref: Note 9) the Board awarded its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 100,000 shares of common stock at an exercise price of $0.50 per share, (ii) an option to purchase 100,000 shares of common stock exercisable on July 15, 2024 at an exercise price of $0.50 per share and (iii) an option to purchase 100,000 shares of common stock exercisable on July 15, 2025 at an exercise price of $0.50 per share, provided the advisors are still providing services to the Company. On July 17, 2023, under the License Agreement Term Sheet (ref: Note 9) the Board awarded its Businesses Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 33,334 shares of common stock at an exercise price of $1.00 per share, (ii) an option to purchase 33,334 shares of common stock exercisable on July 15, 2024 at an exercise price of $1.00 per share and (iii) an option to purchase 33,332 shares of common stock exercisable on July 15, 2025 at an exercise price of $1.00 per share, provided the advisors are still providing services to the Company. On October 1, 2023, the Company entered into an Advisory Board Member Consulting Agreement (the “Agreement”) with Shiri Navon-Venezia (“Venezia”) whereunder Venezia shall provide advisory and consulting services to the Company as part of the Company’s Scientific Advisory Board. As consideration for the services, Venezia has been granted 100,000 three-year stock options at an exercise price of $0.50 per share of which 33,334 stock options shall vest immediately, 33,333 stock options vest on the one-year anniversary date of the Agreement and the remaining 33,333 stock options vest on the two-year anniversary date of the Agreement, provided Venezia is still providing services to the Company. On October 1, 2023, the Company entered into an Advisory Board Member Consulting Agreement (the “Agreement”) with Dr. Motti Ratmansky (“Ratmansky”) whereunder Ratmansky shall continue to provide advisory and consulting services to the Company as part of the Company’s Scientific Advisory Board. As consideration for the services Ratmansky has been granted a five (5) year fully vested stock option to purchase 50,000 shares of the Company’s common stock at an exercise price of $2.00 per share. On November 1, 2023, the Company entered into an Advisory Board Member Consulting Agreement (the “Agreement”) with Dr. Paul Kaye (“Kaye”) whereunder Kaye shall provide advisory and consulting services to the Company as part of the Company’s Scientific Advisory Board. As consideration for the services Kaye has been granted 50,000 three-year stock options at an exercise price of $2.00 per share of which 16,666 vest immediately, 16,667 stock options vest on the one-year anniversary date of the Agreement and the remaining 16,667 stock options vest on the two-year anniversary date of the Agreement, provided Kaye is still providing services to the Company. During the year ended December 31, 2023, various fully vested three-year stock options to purchase 294,999 shares of common stock of the Company previously granted to science advisors and employees expired unexercised. The fair value of new option award during the year ended December 31, 2023 above is estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0 % Expected volatility 229.85%~231 % Risk-free interest rate 4.34 % Expected life (years) 3 Stock Price $ 0.298 ~ 0.40 Exercise Price $ 0.50 ~ 2.00 (a) Stock Options granted to Science Advisors, Business Advisors, Professors and employees The following table is the recognized compensation in respect of the above stock option compensation, which amounts have been allocated as below: Years Ended December 31, 2023 2022 Research and development expenses $ 465,345 $ 160,210 General and administrative expenses 62,491 320,420 Total $ 527,836 $ 480,630 As of December 31, 2023 and 2022, total unrecognized compensation remaining to be recognized in future periods totaled $220,916 and $0, respectively. Details of outstanding options for employees, professors, scientific advisors and business advisors at December 31, 2023 are below: Grant date Vested Unvested Exercise price Expiry Scientific Advisors 12/17/19 33,333 - $ 2.00 12/17/24 12/10/20 100,000 - $ 2.00 12/10/25 12//22/21 325,000 - $ 2.00 12/22/26 12/22/22 325,000 - $ 2.00 12/22/27 07/17/23 50,000 - $ 0.50 07/17/26 07/17/23 50,000 50,000 $ 0.50 07/17/27 07/17/23 50,000 50,000 $ 0.50 07/17/28 07/17/23 50,000 - $ 0.50 07/17/26 07/17/23 50,000 50,000 $ 0.50 07/17/27 07/17/23 50,000 50,000 $ 0.50 07/17/28 Business Advisors 07/17/23 16,667 - $ 1.00 07/17/26 07/17/23 16,667 16,667 $ 1.00 07/17/27 07/17/23 16,666 16,666 $ 1.00 07/17/28 07/17/23 16,667 - $ 1.00 07/17/26 07/17/23 16,667 16,667 $ 1.00 07/17/27 07/17/23 16,666 16,666 $ 1.00 07/17/28 Professors 07/17/23 133,334 - $ 1.00 07/17/26 07/17/23 133,333 133,333 $ 1.00 07/17/27 07/17/23 133,333 133,333 $ 1.00 07/17/28 07/17/23 133,334 - $ 1.00 07/17/26 07/17/23 133,333 133,333 $ 1.00 07/17/27 07/17/23 133,333 133,333 $ 1.00 07/17/28 Professors 10/01/23 50,000 - $ 2.00 10/01/28 Professors 10/01/23 33,334 - $ 0.50 10/01/26 10/01/23 33,333 33,333 $ 0.50 10/01/27 10/01/23 33,333 33,333 $ 0.50 10/01/28 Professors 11/01/23 16,667 - $ 2.00 11/01/26 11/01/23 16,667 16,667 $ 2.00 11/01/27 11/01/23 16,666 16,666 $ 2.00 11/01/28 (b) Stock Options granted to Officers: On December 4, 2022, certain five-year stock options to purchase 600,000 shares of common stock of the Company previously granted to officers expired unexercised. On December 22, 2022, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share, are immediately exercisable and were expensed on issue date. During the year ended December 31, 2023 certain five-year stock options to purchase 650,000 shares of common stock of the Company previously granted to officers expired unexercised. Following are the details of stock options granted to our officers at December 31, 2023: Name Grant date Exercisable Exercise price Expiry Jonah Meer 12/17/19 325,000 $ 2.00 12/17/24 12/10/20 325,000 $ 2.00 12/10/25 12/22/21 325,000 $ 2.00 12/22/26 12/22/22 325,000 $ 2.00 12/22/27 Ido Merfeld 12/17/19 325,000 $ 2.00 12/17/24 12/10/20 325,000 $ 2.00 12/10/25 12/22/21 325,000 $ 2.00 12/22/26 12/22/22 325,000 $ 2.00 12/22/27 As of December 31, 2023 and 2022 there was no unrecognized compensation with respect to the aforementioned stock options remaining to be recognized in future periods. A summary of the activity for the Company’s stock options at December 31, 2023 and 2022, is as follows: December 31, 2023 December 31, 2022 Weighted Average Exercise Weighted Average Remaining Contractual Life Weighted Average Exercise Weighted Average Remaining Contractual Life Shares Price (in years) Shares Price (in years) Outstanding, beginning of period 4,328,332 $ 2 3.03 4,098,332 $ 2 3.08 Granted 1,400,000 $ 0.88 - 975,000 $ 2 - Exercised - $ - - - $ - - Canceled/forfeited (944,999 ) $ 2 - (745,000 ) $ 2 - Outstanding, end of period 4,783,333 $ 1.69 2.91 4,328,332 $ 2 3.03 Options exercisable, end of period 3,883,336 $ 1.87 2.64 4,328,332 $ 2 3.03 Weighted average fair value of options granted $ 1.75 $ 2

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2023
Capital Stock
Capital Stock	Note 11 – Capital Stock Authorized: The Company has authorized 100,000,000 shares of common stock, par value $0.0001, and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001. Series A Preferred Stock: The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the “Stated Value”). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company’s common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on all such matters, regardless of the actual number of shares of Class A Preferred Stock then outstanding. There were 2,000 shares of Series A Preferred Stock issued and outstanding as of December 31, 2023 and December 31, 2022. Common Stock In June 2023, the Company issued 150,000 shares of its common stock to Quick Capital LLC with a value of $52,500 related to a loan amendment (Note 5). In November 2023, the Company issued 60,000 restricted common shares for advisory services. The shares were valued at fair market value on the date of issuance for a total of $16,680 or $0.278 per share. There were 13,649,789 and 13,439,789 shares of common stock issued and outstanding as of December 31, 2023 and 2022, respectively. Common Stock Purchase Warrants As of December 31, 2023 and 2022, the following common stock purchase warrants were outstanding: Warrants Weighted Average Exercise Price Outstanding – December 31, 2021 295,000 $ 1.00 Granted - - Canceled/forfeited - - Exercised - - Outstanding – December 31, 2022 295,000 1.00 Granted - - Canceled/forfeited - - Exercised - - Outstanding – December 31, 2023 295,000 $ 1.00 On June 15, 2021, the Company granted a convertible noteholder a warrant to purchase 115,000 shares of common stock at an exercise price of $1.00, subject to adjustments for full ratchet resets for dilutive issuances at lower prices. (See Note 5(2) above.)

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events
Subsequent Events	Note 12 – Subsequent Events On January 5, 2024 the Company and the holders of various convertible notes with maturity dates in December 2023 and February 2024, respectively (ref: Note 5(1) above) each agreed to extend the terms of their respective notes by a term of 2 years. The Company and Dartmouth agreed in February 2024 to add Professor Chenfeng Ke and Qianming Lin, both formerly of Dartmouth as co-inventors of the patent entitled Techniques for Promoting Neuronal Recovery and to add Dartmouth as co-owner of the patent together with Qrons. The Company has evaluated events for the period through the date of the issuance of these financial statements and determined that there are no additional events requiring disclosure.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Summary of Significant Accounting Policies
Financial Statement Presentation:	Financial Statements:
Fiscal Year End:	Fiscal year end:
Use of Estimates:	Use of Estimates:
Cash Equivalents:	Cash Equivalents:
Research and Development Costs:	Research and Development Costs: Research and Development
Advertising and Marketing Costs:	Advertising and Marketing Costs:
Related Parties:	Related Parties:
Stock Based Compensation and Other Share-Based Payments:	Stock Based Compensation and Other Share-Based Payments: Compensation - Stock Compensation
Fair Value of Financial Instruments	ASC 820, Fair Value Measurements Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities as of December 31, 2023 and 2022: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of December 31, 2023: Liabilities Derivative liabilities $ - $ - $ 373,718 As of December 31, 2022: Liabilities Derivative liabilities $ - $ - $ 358,775
Warrants:	Warrants: Derivatives and Hedging
Income taxes:	Income taxes: Income Taxes
Basic and Diluted Loss Per Share:	Basic and Diluted Loss Per Share Earnings Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The table below reflects the potentially dilutive securities outstanding during each reporting period: December 31, 2023 December 31, 2022 Research warrants at 3% of issued and outstanding shares 409,494 403,194 Convertible notes 846,009 460,000 Series A preferred shares 700 700 Stock options vested 3,883,336 4,328,332 Stock options not yet vested 899,997 - Stock purchase warrants 295,000 295,000 Total 6,334,536 5,487,226
Recently Issued Accounting Pronouncements	Adopted In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company’s operations, financial position or cash flows.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Significant Accounting Policies
Schedule of fair value of derivative liabilities	Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of December 31, 2023: Liabilities Derivative liabilities $ - $ - $ 373,718 As of December 31, 2022: Liabilities Derivative liabilities $ - $ - $ 358,775
Schedule of reflects the potentially dilutive securities	December 31, 2023 December 31, 2022 Research warrants at 3% of issued and outstanding shares 409,494 403,194 Convertible notes 846,009 460,000 Series A preferred shares 700 700 Stock options vested 3,883,336 4,328,332 Stock options not yet vested 899,997 - Stock purchase warrants 295,000 295,000 Total 6,334,536 5,487,226

Convertible Note Related Part_2

Convertible Note Related Party and Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Convertible Note Related Party and Derivative Liabilities
Schedule of carrying value of convertible notes	December 31 2023 December 31, 2022 Face value of certain convertible notes $ - $ 25,000 Convertible notes extinguished - (25,000 ) Carrying value $ - $ -
Schedule of intrest on the convertible note	For Years Ended December 31, 2023 2022 Interest on the convertible notes $ - $ 1,424
Schedule of derivative liability associated with the conversion	Balance at December 31, 2020 $ 61,682 Change in fair value 11,417 Balance at December 31, 2021 73,099 Change in fair value (73,099 ) Balance at December 31, 2022 $ -
Schedule of derivative liability based upon management assumptions	Commitment Date December 31, 2021 September 27, 2022 Expected dividends 0 0 0 Expected volatility 101%-103 % 181%-182 % 101%~56 % Expected term 0.92 - 1 year 0.67 - 0.74 year 0 year Risk free interest rate 1.33 % 1.06 % 2.22 %

Convertible Note and Derivati_2

Convertible Note and Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Convertible Note and Derivative Liabilities
Carrying value of these convertible notes	December 31, 2023 December 31, 2022 Face value of certain convertible notes, long term $ 80,000 $ 80,000 Carrying value, long term $ 80,000 $ 80,000
Interest expenses associated with the convertible notes	Years Ended December 31, 2023 2022 Amortization on debt discount $ - $ 541 Interest on the convertible notes 6,400 6,400 Total $ 6,400 $ 6,941
Fair value of the derivative liability associated with the conversion feature	Balance at December 31, 2021 $ 157,490 Change in fair value (100,457 ) Balance at December 31, 2022 57,033 Change in fair value 27,965 Balance at December 31, 2023 $ 84,998
Commitment and re-measurement dates	Commitment Date December 31, 2022 December 31, 2023 Expected dividends 0 0 0 Expected volatility 154%-173 % 194.20%-201.98 % 170.40%-224.62 % Expected term 2.10 years 1.08 - 1.22 years 2.08 – 2.22 years Risk free interest rate 1.42-1.65 % 4.41 % 4.23 %
The carrying value of the Quick Note is as follows	December 31, 2023 December 31, 2022 Face value of Quick Note $ 200,000 $ 150,000 Less: unamortized discount (14,024 ) (21,753 ) Carrying value $ 185,976 $ 128,247
Interest expenses associated with the conversion	Years ended December 31, 2023 2022 Amortization of debt discount $ 35,091 $ 55,655 Default interest 38,000 62,100 Interest on the convertible notes 19,934 4,973 Total $ 93,025 $ 122,728
Details of the valuation shares of common stock	150,000 common stock issued $ 52,500 Extinguish derivative liability – convertible note (22,679 ) Unamortized debt discount 2,099 Derivative Liability associated with warrants 2,012 Loss on extinguishment of debt upon amended $ 33,932
Fair value of the derivative liability associated with the conversion feature is summarized as follows	Balance at December 31, 2022 $ 301,742 Extinguish – convertible note associated with amended (22,679 ) Debt discount, day one, amended convertible note payable 29,461 Derivative Liability associated with warrants 2,012 Change in fair value – convertible note 10,766 Change in fair value – warrants (32,582 ) Balance at December 31, 2023 $ 288,720
Fair value at the commitment and re-measurement dates for the Company's derivative liabilities	Convertible note: Commitment Date December 31, 2022 December 31, 2023 June 15, 2023 Expected dividends 0 0 0 0 Expected volatility 307.10 % 119.70 % 176.9 % 95.60 % Expected term 1 year 0.45 years 0.46 year 1 year Risk free interest rate 0.18 % 4.37 % 4.78 % 4.83 % Warrants: Commitment Date December 31, 2022 December 31, 2023 June 15, 2023 Expected dividends 0 0 0 0 Expected volatility 201.70 % 219.10 % 210.80 % 207.50 % Expected term 5 years 4.45 years 4.46 years 5.00 years Risk free interest rate 0.65 % 4.27 % 4.53 % 4.53 %

Stock Plan (Tables)

Stock Plan (Tables)	12 Months Ended
	Dec. 31, 2023
Stock Plan
Summary of assumptions at the measurement date	Measurement date Dividend yield 0 % Expected volatility 229.85%~231 % Risk-free interest rate 4.34 % Expected life (years) 3 Stock Price $ 0.298 ~ 0.40 Exercise Price $ 0.50 ~ 2.00
Summary of the activity for unrecognized compensation in respect of the above stock option compensation	Years Ended December 31, 2023 2022 Research and development expenses $ 465,345 $ 160,210 General and administrative expenses 62,491 320,420 Total $ 527,836 $ 480,630
Summary of the activity for recognized compensation in respect of the above stock option compensation	Grant date Vested Unvested Exercise price Expiry Scientific Advisors 12/17/19 33,333 - $ 2.00 12/17/24 12/10/20 100,000 - $ 2.00 12/10/25 12//22/21 325,000 - $ 2.00 12/22/26 12/22/22 325,000 - $ 2.00 12/22/27 07/17/23 50,000 - $ 0.50 07/17/26 07/17/23 50,000 50,000 $ 0.50 07/17/27 07/17/23 50,000 50,000 $ 0.50 07/17/28 07/17/23 50,000 - $ 0.50 07/17/26 07/17/23 50,000 50,000 $ 0.50 07/17/27 07/17/23 50,000 50,000 $ 0.50 07/17/28 Business Advisors 07/17/23 16,667 - $ 1.00 07/17/26 07/17/23 16,667 16,667 $ 1.00 07/17/27 07/17/23 16,666 16,666 $ 1.00 07/17/28 07/17/23 16,667 - $ 1.00 07/17/26 07/17/23 16,667 16,667 $ 1.00 07/17/27 07/17/23 16,666 16,666 $ 1.00 07/17/28 Professors 07/17/23 133,334 - $ 1.00 07/17/26 07/17/23 133,333 133,333 $ 1.00 07/17/27 07/17/23 133,333 133,333 $ 1.00 07/17/28 07/17/23 133,334 - $ 1.00 07/17/26 07/17/23 133,333 133,333 $ 1.00 07/17/27 07/17/23 133,333 133,333 $ 1.00 07/17/28 Professors 10/01/23 50,000 - $ 2.00 10/01/28 Professors 10/01/23 33,334 - $ 0.50 10/01/26 10/01/23 33,333 33,333 $ 0.50 10/01/27 10/01/23 33,333 33,333 $ 0.50 10/01/28 Professors 11/01/23 16,667 - $ 2.00 11/01/26 11/01/23 16,667 16,667 $ 2.00 11/01/27 11/01/23 16,666 16,666 $ 2.00 11/01/28
Schedule of stock options granted to our officers	Name Grant date Exercisable Exercise price Expiry Jonah Meer 12/17/19 325,000 $ 2.00 12/17/24 12/10/20 325,000 $ 2.00 12/10/25 12/22/21 325,000 $ 2.00 12/22/26 12/22/22 325,000 $ 2.00 12/22/27 Ido Merfeld 12/17/19 325,000 $ 2.00 12/17/24 12/10/20 325,000 $ 2.00 12/10/25 12/22/21 325,000 $ 2.00 12/22/26 12/22/22 325,000 $ 2.00 12/22/27
Schedule of stock option activity	December 31, 2023 December 31, 2022 Weighted Average Exercise Weighted Average Remaining Contractual Life Weighted Average Exercise Weighted Average Remaining Contractual Life Shares Price (in years) Shares Price (in years) Outstanding, beginning of period 4,328,332 $ 2 3.03 4,098,332 $ 2 3.08 Granted 1,400,000 $ 0.88 - 975,000 $ 2 - Exercised - $ - - - $ - - Canceled/forfeited (944,999 ) $ 2 - (745,000 ) $ 2 - Outstanding, end of period 4,783,333 $ 1.69 2.91 4,328,332 $ 2 3.03 Options exercisable, end of period 3,883,336 $ 1.87 2.64 4,328,332 $ 2 3.03 Weighted average fair value of options granted $ 1.75 $ 2

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2023
Capital Stock
Schedule of common stock purchase warrants outstanding	Warrants Weighted Average Exercise Price Outstanding – December 31, 2021 295,000 $ 1.00 Granted - - Canceled/forfeited - - Exercised - - Outstanding – December 31, 2022 295,000 1.00 Granted - - Canceled/forfeited - - Exercised - - Outstanding – December 31, 2023 295,000 $ 1.00

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Level 1 [Member]
Liabilities
Derivative liabilities	$ 0	$ 0
Level 2 [Member]
Liabilities
Derivative liabilities	0	0
Level 3 [Member]
Liabilities
Derivative liabilities	$ 373,718	$ 358,775

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Potentially dilutive securities net loss per share	6,334,536	5,487,226
Series A Preferred Shares [Member]
Potentially dilutive securities net loss per share	700	700
Stock options vested [Member]
Potentially dilutive securities net loss per share	3,883,336	4,328,332
Research Warrants at 3% of issued and outstanding shares [Member]
Potentially dilutive securities net loss per share	409,494	403,194
Convertible Note [Member]
Potentially dilutive securities net loss per share	846,009	460,000
Stock purchase warrants [Member]
Potentially dilutive securities net loss per share	295,000	295,000
Stock options not yet vested [Member]
Potentially dilutive securities net loss per share	899,997

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies
Research and development costs	$ 462,459	$ 194,406
Advertising or marketing costs	$ 0	$ 0

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Going Concern
Proceeds from related party advances	$ 66,000	$ 72,500

Convertible Note Related Part_3

Convertible Note Related Party and Derivative Liabilities (Details) - Related Party Debt [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Face value of certain convertible notes	$ 0	$ 25,000
Convertible notes extinguish	0	(25,000)
Carrying value	$ 0	$ 0

Convertible Note Related Part_4

Convertible Note Related Party and Derivative Liabilities (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Interest on the convertible notes	$ 19,934	$ 4,973
Related Party Debt [Member]
Interest on the convertible notes	$ 0	$ 1,424

Convertible Note Related Part_5

Convertible Note Related Party and Derivative Liabilities (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Beganing balance	$ 358,775
Changes in Fair Value	27,965	$ (100,457)
Ending balance	288,720	358,775
Derivative Liabilities [Member]
Beganing balance	$ 0	73,099	$ 61,682
Changes in Fair Value		(73,099)	11,417
Ending balance		$ 0	$ 73,099

Convertible Note Related Part_6

Convertible Note Related Party and Derivative Liabilities (Details 3)	9 Months Ended	12 Months Ended
	Sep. 27, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Minimum [Member]
Expected term		2 years 29 days	1 year 2 months 19 days
Maximum [Member]
Expected term		2 years 2 months 19 days	1 year 29 days
Related Party Debt [Member]
Expected dividends	0%			0%
Risk free interest rate	2.22%			1.06%
Expected term				0 years
Related Party Debt [Member] | Minimum [Member]
Expected volatility	101%			181%
Expected term				8 months 1 day
Related Party Debt [Member] | Maximum [Member]
Expected volatility	56%			182%
Expected term				8 months 26 days
Related Party Debt [Member] | Commitment Date [Member]
Expected dividends		0%
Risk free interest rate		1.33%
Related Party Debt [Member] | Commitment Date [Member] | Minimum [Member]
Expected volatility		101%
Expected term		11 months 1 day
Related Party Debt [Member] | Commitment Date [Member] | Maximum [Member]
Expected volatility		103%
Expected term		1 year

Convertible Note Related Part_7

Convertible Note Related Party and Derivative Liabilities (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Sep. 27, 2022	Sep. 27, 2017	Dec. 31, 2023	Dec. 31, 2022
Interest rate per annum			8%
Principal amount - related party convertible note modified to 6% promissory note	$ 35,873
Aggregate principal amount - related party convertible note modified to 6% promissory note	25,000
Accrued interest payable - related party convertible note modified to 6% promissory note	10,873
Cubesquare Llc [Member]
Convertible debenture agreement		$ 15,000
Ownership percentage			25%
Interest rate per annum		8%	6%
Conversion, description		Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare	the Company’s Chief Executive Officer is the managing partner and its President is a 25% owner of CubeSquare. The Company received proceeds of $10,000 during fiscal 2016 (“Note 1”). Note 1 bears interest at 8% per annum and was due on September 1, 2017. Interest accrues from September 1, 2016 and is payable on maturity. Interest is payable, at the lender’s option, in cash or common stock. Any portion of the loan and unpaid interest is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price of the greater of (i) $0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender
Accounts payable and accrued liabilities related party			$ 0	$ 0
Principal amount - related party convertible note modified to 6% promissory note	35,873
Aggregate principal amount - related party convertible note modified to 6% promissory note	25,000
Accrued interest payable - related party convertible note modified to 6% promissory note	$ 10,873

Convertible Note and Derivati_3

Convertible Note and Derivative Liabilities (Details) - Derivative Liabilities [Member] - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Face value of certain convertible notes, long term	$ 80,000	$ 80,000
Carrying value, long term	$ 80,000	$ 80,000

Convertible Note and Derivati_4

Convertible Note and Derivative Liabilities (Details 1) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 15, 2023	Dec. 31, 2023	Dec. 31, 2022
Interest on the convertible notes		$ 93,025	$ 122,728
Amortization on debt discount	$ 2,099	35,091	55,655
Convertible Note [Member]
Interest on the convertible notes		6,400	6,400
Amortization on debt discount		0	541
Total		$ 6,400	$ 6,941

Convertible Note and Derivati_5

Convertible Note and Derivative Liabilities (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Convertible Note and Derivative Liabilities
Balance at beginning	$ 57,033	$ 157,490
Change in fair value	27,965	(100,457)
Balance at ending	$ 84,998	$ 57,033

Convertible Note and Derivati_6

Convertible Note and Derivative Liabilities (Details 3)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Expected dividend	0%	0%
Risk free interest	4.23%	4.41%
Minimum [Member]
Expected volatility	170.40%	194.20%
Expected term	2 years 29 days	1 year 2 months 19 days
Maximum [Member]
Expected volatility	224.62%	201.98%
Expected term	2 years 2 months 19 days	1 year 29 days
Commitment Date [Member]
Expected dividend	0%
Expected term	2 years 1 month 6 days
Commitment Dates Minimum [Member]
Risk free interest	1.42%
Expected volatility	154%
Commitment Dates Maximum [Member]
Risk free interest	1.65%
Expected volatility	173%

Convertible Note and Derivati_7

Convertible Note and Derivative Liabilities (Details 4) - Quick Note [Member] - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Face value of Quick Note	$ 200,000	$ 150,000
Less: unamortized discount	(14,024)	(21,753)
Carrying value	$ 185,976	$ 128,247

Convertible Note and Derivati_8

Convertible Note and Derivative Liabilities (Details 5) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 15, 2023	Dec. 31, 2023	Dec. 31, 2022
Convertible Note and Derivative Liabilities
Amortization of debt discount	$ 2,099	$ 35,091	$ 55,655
Default interest		38,000	62,100
Interest on the convertible notes		19,934	4,973
Total		$ 93,025	$ 122,728

Convertible Note and Derivati_9

Convertible Note and Derivative Liabilities (Details 6) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 15, 2023	Dec. 31, 2023	Dec. 31, 2022
Convertible Note and Derivative Liabilities
150,000 common stock issued amount	$ 52,500
Extinguish derivative liability - convertible note	(22,679)
Unamortized debt discount	2,099	$ 35,091	$ 55,655
Derivative Liability associated with warrants	2,012	$ 2,012	$ 15,416
Loss on extinguishment of debt upon amended	$ 33,932

Convertible Note and Derivat_10

Convertible Note and Derivative Liabilities (Details 7) - Warrants [Member] - Convertible Note June [Member]	12 Months Ended
	Dec. 31, 2023 USD ($)
Balance at beginning	$ 301,742
Extinguish - convertible note associated with amended	(22,679)
Debt discount, day one, amended convertible note payable	29,461
Derivative Liability associated with warrants	2,012
Change in fair value - convertible note	10,766
Change in fair value - warrants	(32,582)
Balance at ending	$ 288,720

Convertible Note and Derivat_11

Convertible Note and Derivative Liabilities (Details 8)	6 Months Ended	12 Months Ended
	Jun. 15, 2023	Dec. 31, 2023	Dec. 31, 2022
Expected dividend		0%	0%
Risk free interest		4.23%	4.41%
Commitment Date Convertible Note [Member]
Expected dividend		0%
Expected volatility		307.10%
Expected term		1 year
Risk free interest		0.18%
Warrants [Member]
Expected dividend	0%	0%	0%
Expected volatility	207.50%	210.80%	219.10%
Expected term	5 years	4 years 5 months 15 days	4 years 5 months 12 days
Risk free interest	4.53%	4.53%	4.27%
Commitment And Warrants [Member]
Expected dividend		0%
Expected volatility		201.70%
Expected term		5 years
Risk free interest		0.65%
Convertible Note [Member]
Expected dividend	0%	0%	0%
Expected volatility	95.60%	176.90%	119.70%
Expected term	1 year	5 months 15 days	5 months 12 days
Risk free interest	4.83%	4.78%	4.37%

Convertible Note and Derivat_12

Convertible Note and Derivative Liabilities (Details Narrative) - USD ($)	1 Months Ended					9 Months Ended
	Jun. 15, 2023	Jun. 15, 2022	Jun. 15, 2021	Feb. 19, 2020	Dec. 31, 2019	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Accounts payable and accrued liabilities							$ 155,357	$ 128,285
Accrued interest	$ 162,000	$ 124,200
Accrued interest outstanding	$ 243,000	$ 186,300
Warrant maturity date	Jun. 15, 2028	Jun. 15, 2027
Restricted common stock valued	$ 52,500	$ 76,350
Issuance of common stock shares	$ 150,000	$ 150,000
Interest rate per annum							8%
Purchase shares of common stock						800,000
Derivative Liabilities [Member]
Accounts payable and accrued liabilities							$ 25,669	19,269
Interest rate per annum				8%	8%
Purchase shares of common stock				10,000	70,000
Conversion, description				The note is due on February 19, 2022 and is convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; or (c) such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 10,000 shares of common stock at an exercise price of $1.00	Such notes were due on December 31, 2021 and are convertible into shares of our common stock at a conversion price for each share of common stock equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) so long as lower than (a) or (b), such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00
Investment			$ 100,000
Legal and transaction expences			3,500
Principal amount			$ 115,000	$ 10,000	$ 70,000
Discount rate			10%
Aggregate purchase of common stock			115,000
Exercise price			$ 1	$ 1
Conversion price of common stock			$ 0.50
Liquidated damages payment, daily			$ 2,000
Interest due penalty			50%
Unpaid interest [Member]
Accounts payable and accrued liabilities							$ 8,723	$ 789

Unsecured ShortTerm Advance f_2

Unsecured ShortTerm Advance from Third Party (Details Narrative)	Jun. 20, 2019 USD ($)
Unsecured ShortTerm Advance from Third Party
Unsecured short-term advances	$ 100,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)		1 Months Ended		12 Months Ended
	May 01, 2019	Sep. 27, 2022	Aug. 20, 2019	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2019
Accounts payable and accrued liabilities - related party				$ 21,397	$ 15,234
Interest expense				2,152	560
Principal amount - related party convertible note modified to 6% promissory note		$ 35,873
Aggregate principal amount - related party convertible note modified to 6% promissory note		25,000
Accrued interest payable - related party convertible note modified to 6% promissory note		10,873
Cubesquare Llc [Member]
Due to related party	$ 50,000					$ 10,000
Ownership percentage	25%
Interest expense				4,011	4,000
Principal amount - related party convertible note modified to 6% promissory note		35,873
Aggregate principal amount - related party convertible note modified to 6% promissory note		25,000
Accrued interest payable - related party convertible note modified to 6% promissory note		$ 10,873
Jonah Meer [Member]
Accounts payable and accrued liabilities - related party				60,129	26,268
Due to related party					72,500	$ 70,000	$ 135,000
Additional advances received				33,860
Advances from Related Parties				338,500	277,500
Advances amount				61,000
Ido Merfeld [Member]
Accounts payable and accrued liabilities - related party				1,765	1,169
Due to related party			$ 50,000		21,000
Additional advances received				596
Advances from Related Parties				76,000	$ 71,000
Advances amount				$ 5,000

Intellectual Property License_2

Intellectual Property License Agreement and Sponsored Research Agreement (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	May 30, 2023	Dec. 31, 2023
Intellectual Property License Agreement and Sponsored Research Agreement
Unpaid reimbursable patent maintenance costs		$ 4,877
Unpaid annual license fee		50,000
Research and development expences		1,000,000
Annual net sales		50,000,000
License fees	$ 25,000
Licence expense		$ 25,000
Annual minimum royalty payment, description		beginning in the first calendar year after the first commercial sale, an annual minimum royalty payment of $500,000, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter
Royalty percentage of net sales		2%

License Agreement Term Sheet _2

License Agreement Term Sheet and Advisory Board Member Consulting Agreement (Details Narrative) - $ / shares	9 Months Ended
	Sep. 30, 2023	Nov. 01, 2023	Oct. 01, 2023	Jun. 15, 2021
Common stock exercise price per share	$ 1			$ 1
Purchase shares of common stock	800,000
Funds description	Qrons is tasked with raising $2 million funds to support Tellurium Research. If within a year after the commencement of the Agreement, Qrons fails to raise at least $2 million, the license will be terminated unless agreed otherwise by the parties
Scientific Advisor
Shares granted	150,000
Term of option	3 years
Option exercise price per share	$ 0.50
Hananel Levy [Member]
Shares granted	50,000
Option exercise price per share	$ 1
Term of option	3 years
Licensing Agreements [Member]
Stock options at an exercise price		$ 2	$ 0.50
Stock options vest on one-year		16,667	33,333
Stock options vest on two-year		16,667	33,333
Vested stock option to purchase			50,000
Common stock at an exercise price			$ 2
Stock options		50,000	100,000
Stock options vest immediately		16,666	33,334

Stock Plan (Details)

Stock Plan (Details) - Measurement Date [Member] - Stock Option [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares
Dividend yield	0%
Expected volatility, Minimum	229.85%
Expected volatility, Maximum	231%
Risk-free interest rate	4.34%
Expected life (years)	3 years
Stock Price, Minimum	$ 0.298
Stock Price, Maximum	0.40
Exercise Price, Minimum	0.50
Exercise Price, Maximum	$ 2

Stock Plan (Details 1)

Stock Plan (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock option compensation allocated expenses	$ 527,836	$ 480,630
Research and Development Expense [Member]
Stock option compensation allocated expenses	465,345	160,210
General and Administrative Expense [Member]
Stock option compensation allocated expenses	$ 62,491	$ 320,420

Stock Plan (Details 2)

Stock Plan (Details 2)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Grant 6 | Scientific Advisor
Expiry	Jul. 17, 2027
Exercise price | $ / shares	$ 0.50
Vested	50,000
Grant date	Jul. 17, 2023
Unvested	50,000
Grant 7 | Scientific Advisor
Expiry	Jul. 17, 2028
Exercise price | $ / shares	$ 0.50
Vested	50,000
Grant date	Jul. 17, 2023
Unvested	50,000
Grant 8 | Scientific Advisor
Expiry	Jul. 17, 2026
Exercise price | $ / shares	$ 0.50
Vested	50,000
Grant date	Jul. 17, 2023
Grant 9 | Scientific Advisor
Expiry	Jul. 17, 2027
Exercise price | $ / shares	$ 0.50
Vested	50,000
Grant date	Jul. 17, 2023
Unvested	50,000
Grant 10 | Scientific Advisor
Expiry	Jul. 17, 2028
Exercise price | $ / shares	$ 0.50
Vested	50,000
Grant date	Jul. 17, 2023
Unvested	50,000
Grant | Business Advisor [Member]
Expiry	Jul. 17, 2026
Exercise price | $ / shares	$ 1
Vested	16,667
Grant date	Jul. 17, 2023
Grant 4 | Professors [Member]
Expiry	Jul. 17, 2027
Exercise price | $ / shares	$ 1
Vested	133,333
Grant date	Jul. 17, 2023
Unvested	133,333
Grant 5 | Scientific Advisor
Expiry	Jul. 17, 2026
Exercise price | $ / shares	$ 0.50
Vested	50,000
Grant date	Jul. 17, 2023
Grant 5 | Business Advisor [Member]
Expiry	Jul. 17, 2028
Exercise price | $ / shares	$ 1
Vested	16,666
Grant date	Jul. 17, 2023
Unvested	16,666
Grant 5 | Professors [Member]
Expiry	Jul. 17, 2028
Exercise price | $ / shares	$ 1
Vested	133,333
Grant date	Jul. 17, 2023
Unvested	133,333
Grant 1 | Scientific Advisor
Expiry	Dec. 17, 2024
Exercise price | $ / shares	$ 2
Vested	33,333
Grant date	Dec. 17, 2019
Grant 1 | Business Advisor [Member]
Expiry	Jul. 17, 2027
Exercise price | $ / shares	$ 1
Vested	16,667
Grant date	Jul. 17, 2023
Unvested	16,667
Grant 1 | Professors [Member]
Expiry	Jul. 17, 2027
Exercise price | $ / shares	$ 1
Vested	133,333
Grant date	Jul. 17, 2023
Unvested	133,333
Grant 1 | Professors 3 [Member]
Expiry	Nov. 01, 2027
Exercise price | $ / shares	$ 2
Vested	16,667
Grant date	Nov. 01, 2023
Unvested	16,667
Grant 2 | Scientific Advisor
Expiry	Dec. 10, 2025
Exercise price | $ / shares	$ 2
Vested	100,000
Grant date	Dec. 10, 2020
Grant 2 | Business Advisor [Member]
Expiry	Jul. 17, 2028
Exercise price | $ / shares	$ 1
Vested	16,666
Grant date	Jul. 17, 2023
Unvested	16,666
Grant 2 | Professors [Member]
Expiry	Nov. 01, 2023
Exercise price | $ / shares	$ 1
Vested	133,333
Grant date	Jul. 17, 2023
Unvested	133,333
Grant 2 | Professors 2 [Member]
Expiry	Oct. 01, 2027
Exercise price | $ / shares	$ 0.50
Vested	33,333
Grant date	Oct. 01, 2023
Unvested	33,333
Grant 2 | Professors 3 [Member]
Expiry	Nov. 01, 2028
Exercise price | $ / shares	$ 0.50
Vested	33,333
Grant date	Oct. 01, 2023
Unvested	33,333
Grant | Professors 1
Expiry	Oct. 01, 2028
Exercise price | $ / shares	$ 2
Vested	50,000
Grant date	Jul. 17, 2023
Grant | Professors 2 [Member]
Expiry	Jul. 17, 2026
Exercise price | $ / shares	$ 0.50
Vested	33,334
Grant date	Oct. 01, 2023
Grant | Professors 3 [Member]
Expiry	Nov. 01, 2026
Exercise price | $ / shares	$ 2
Vested	16,666
Grant date	Nov. 01, 2023
Unvested	16,666
Grant 3 | Scientific Advisor
Expiry	Dec. 22, 2026
Exercise price | $ / shares	$ 2
Vested	325,000
Grant date	Dec. 22, 2021
Grant 3 | Business Advisor [Member]
Expiry	Jul. 17, 2026
Exercise price | $ / shares	$ 1
Vested	16,667
Grant date	Jul. 17, 2023
Grant 3 | Professors [Member]
Expiry	Jul. 17, 2026
Exercise price | $ / shares	$ 1
Vested	133,334
Grant date	Jul. 17, 2023
Grant 4 | Scientific Advisor
Expiry	Dec. 22, 2027
Exercise price | $ / shares	$ 2
Vested	325,000
Grant date	Dec. 22, 2022
Grant 4 | Business Advisor [Member]
Expiry	Jul. 17, 2027
Exercise price | $ / shares	$ 1
Vested	16,667
Grant date	Jul. 17, 2023
Unvested	16,667
Grant | Professors [Member]
Expiry	Oct. 01, 2026
Exercise price | $ / shares	$ 2
Vested	133,334
Grant date	Oct. 01, 2023

Stock Plan (Details 3)

Stock Plan (Details 3)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Grant 1 | Jonah Meer [Member]
Expiry	Dec. 17, 2024
Exercise price | $ / shares	$ 2
Exercisable | shares	325,000
Grant date	Dec. 17, 2019
Grant 1 | Ido Merfeld [Member]
Expiry	Dec. 17, 2024
Exercise price | $ / shares	$ 2
Exercisable | shares	325,000
Grant date	Dec. 17, 2019
Grant 2 | Jonah Meer [Member]
Expiry	Dec. 10, 2025
Exercise price | $ / shares	$ 2
Exercisable | shares	325,000
Grant date	Dec. 10, 2020
Grant 2 | Ido Merfeld [Member]
Expiry	Dec. 10, 2025
Exercise price | $ / shares	$ 2
Exercisable | shares	325,000
Grant date	Dec. 10, 2020
Grant 3 | Jonah Meer [Member]
Expiry	Dec. 22, 2026
Exercise price | $ / shares	$ 2
Exercisable | shares	325,000
Grant date	Dec. 22, 2021
Grant 3 | Ido Merfeld [Member]
Expiry	Dec. 22, 2026
Exercise price | $ / shares	$ 2
Exercisable | shares	325,000
Grant date	Dec. 22, 2021
Grant 4 | Jonah Meer [Member]
Expiry	Dec. 22, 2027
Exercise price | $ / shares	$ 2
Exercisable | shares	325,000
Grant date	Dec. 22, 2022
Grant 4 | Ido Merfeld [Member]
Expiry	Dec. 22, 2027
Exercise price | $ / shares	$ 2
Exercisable | shares	325,000
Grant date	Dec. 22, 2022

Stock Plan (Details 4)

Stock Plan (Details 4) - Stock Options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Number of Options Outstanding, Beginning balance	4,328,332	4,098,332
Number of Options, Granted	1,400,000	975,000
Number of Options Canceled, forfeited, or expired	(944,999)	(745,000)
Number of Options Outstanding, Ending balance	4,783,333	4,328,332
Numbeer of Options exercisable, Ending balance	3,883,336	4,328,332
Weighted Average Exercise Price, Beginning balance	$ 2	$ 2
Weighted Average Exercise Price Granted	0.88	2
Weighted Average Exercise Price Exercised	0	0
Weighted Average Exercise Price Canceled, forfeited, or expired	2	2
Weighted Average Exercise Price, Ending balance	1.69	2
Weighted Average Exercise Price Exercisable, Ending balance	1.87	2
Weighted average fair value of options, granted	$ 1.75	$ 2
Remaining Contract term, Beginning balance	3 years 10 days	3 years 29 days
Remaining Contract term, Ending balance	2 years 10 months 28 days	3 years 10 days
Remaining Contract term, Exercisable	2 years 7 months 20 days	3 years 10 days

Stock Plan (Details Narrative)

Stock Plan (Details Narrative) - USD ($)		1 Months Ended		12 Months Ended
	Dec. 04, 2022	Jul. 17, 2023	Dec. 22, 2022	Dec. 31, 2023	Dec. 31, 2022	Nov. 01, 2023	Oct. 01, 2023
Unrecognized compensation				$ 220,916	$ 0
Licensing Agreements [Member]
Stock options at an exercise price						$ 2	$ 0.50
Stock options vest on one-year						16,667	33,333
Stock options vest on two-year						16,667	33,333
Vested stock option to purchase							50,000
Common stock at an exercise price							$ 2
Stock options						50,000	100,000
Stock options vest immediately						16,666	33,334
Three Year Stock Option [Member]
Exercise price		$ 1
Exercisable option to purchase		266,668
Three Year Stock Option One [Member]
Exercise price		$ 0.50
Exercisable option to purchase		100,000
Three Year Stock Option Two [Member]
Exercise price		$ 1
Exercisable option to purchase		33,334
Stock Options Granted To Officers [Member]
Granted an option to purchase of common stock				650,000
July 15, 2024 [Member] | Three Year Stock Option [Member]
Exercise price				$ 1
Exercisable option to purchase				266,666
July 15, 2025 [Member] | Three Year Stock Option [Member]
Exercise price				$ 1
Exercisable option to purchase				266,666
July 15, 2024 One [Member] | Three Year Stock Option [Member]
Exercise price				$ 0.50
Exercisable option to purchase				100,000
July 15, 2025 One [Member] | Three Year Stock Option [Member]
Exercise price				$ 0.50
Exercisable option to purchase				100,000
July 15, 2024 Two [Member] | Three Year Stock Option [Member]
Exercise price				$ 1
Exercisable option to purchase				33,334
July 15, 2025 Two [Member] | Three Year Stock Option [Member]
Exercise price				$ 1
Exercisable option to purchase				33,332
Stock Options Granted To Science Advisors and Employees [Member]
Granted an option to purchase of common stock	600,000		325,000	294,999	145,000
Weighted average excercise price			$ 2
Stock Options Granted To Science Advisors and Employees [Member] | Licensing Agreements [Member]
Stock options at an exercise price						$ 2	$ 0.50
Stock options vest on one-year						16,667	33,333
Stock options vest on two-year						16,667	33,333
Vested stock option to purchase							50,000
Common stock at an exercise price							$ 2
Stock options						50,000	100,000
Stock options vest immediately						16,666	33,334

Capital Stock (Details)

Capital Stock (Details) - Common Stock Purchase Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Warrants Outstanding, Beginning balance	295,000	295,000
Warrants Outstanding, Ending balance	295,000	295,000
Weighted Average Exercise Price, Beginning balance	$ 1	$ 1
Weighted Average Exercise Price Granted	0	0
Weighted Average Exercise Price Canceled/Forfeited	0	0
Weighted Average Exercise Price Exercised	0	0
Weighted Average Exercise Price, Ending balance	$ 1	$ 1

Capital Stock (Details Narrativ

Capital Stock (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 15, 2021	Dec. 31, 2023	Nov. 30, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Common Stock, Shares Authorized		100,000,000				100,000,000
Common Stock, Par or Stated Value Per Share		$ 0.0001				$ 0.0001
Common stock exercise price per share	$ 1			$ 1
Common Stock, Shares Issued		13,649,789				13,439,789
Common Stock, value		$ 1,365				$ 1,344
Common Stock, Shares Outstanding		13,649,789				13,439,789
Number of common shares issued for warrants	115,000
Preferred Stock, Shares Authorized		10,000				10,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001				$ 0.001
Preferred Stock, Shares Issued		2,000				2,000
Preferred Shares, shares outstanding		2,000				2,000
Quick Capital LLC [Member]
Common Stock, Shares Issued					150,000
Common Stock, value					$ 52,500
November 2023 [Member]
Common Stock, Par or Stated Value Per Share			$ 0.278
Common Stock, Shares Issued			60,000
Common Stock, value			$ 16,680
Series A Preferred Stock [Member]
Redemption description		The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the “Stated Value”).
Preferred Stock, Shares Issued		2,000				2,000
Preferred Shares, shares outstanding		2,000				2,000